Download a PDF of the Research Summary. A total of 234 patients were enrolled; 117 were assigned to the alteplase group and 117 to the standard treatment group. The median score on the National ...

The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

Researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group vs the standard treatment group. HealthDay News — For patients with ...

Boehringer Ingelheim's latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

Extending the treatment window for intravenous thrombolysis beyond 4.5 hours may benefit patients with posterior circulation ischemic stroke. New research findings are summarized in a short video.

For patients with posterior circulation stroke, alteplase administered at 4.5 to 24 hours after onset increases frequency of functional independence.

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...

Alteplase administered 4.5 to 24 hours after mild posterior circulation ischemic stroke onset increases the likelihood of functional independence at 90 days compared to standard care.

F RIDAY, April 4, 2025 (HealthDay News) -- For patients with mainly mild posterior circulation ischemic stroke who do not receive thrombectomy, alteplase administered at 4.5 to 24 hours after ...